Rotavirus vaccines and vaccination in Latin America
Autor(a) principal: | |
---|---|
Data de Publicação: | 2000 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Digital do Instituto Evandro Chagas (Patuá) |
Texto Completo: | https://patua.iec.gov.br/handle/iec/3238 |
Resumo: | Worldwide, rotaviruses account for more than 125 million cases of infantile gastroenteritis and nearly 1 million deaths per year, mainly in developing countries. Rather than other control measures, vaccination is most likely to have a major impact on rotavirus disease incidence. The peak incidence of rotavirus diarrhea occurs between 6 and 24 months of age. In developing countries, however, cases are not uncommon among children younger than 6 months. G serotypes 1 to 4 are responsible for most disease, but there are indications that in Brazil that G type 5 is of emerging epidemiological importance. Both homotypic and heterotypic responses are elicited during natural rotavirus infection, and the immunological response at the intestinal mucosal surface is probably the more consistent predictor of clinical immunity. With the primary objective of protecting children against life-threatening dehydrating diarrhea, many approaches to rotavirus vaccine development have been attempted. One vaccine, the tetravalent rhesus-human reassortant rotavirus vaccine (RRV-TV), was given licensing approval in the United States of America, introduced to the market, and later withdrawn. A number of studies have found better efficacy of RRV-TV in developed countries than in developing ones. Field trials with a 4 10 plaque-forming units (PFU) preparation of RRVTV have been carried out in two countries in Latin America, Brazil and Peru. Those trials yielded protective efficacy rates against all rotavirus diarrhea ranging from 18% to 35%. Data from a large catchment trial in Venezuela with a higher RRV-TV dose, of 4 10 PFU/dose, indicated an efficacy rate of 48% against all rotavirus diarrhea and 88% against severe rotavirus diarrhea. It appears that breast-feeding does not compromise the efficacy of RRV-TV if three doses of the vaccine are administered. Similarly, possible interference of oral poliovirus vaccine with the “take” of the rotavirus vaccine can be overcome by giving three doses of the rotavirus vaccine or by using a higher-titer formulation of it. Wild enteroviruses, however, may cause primary rotavirus vaccine failure in developing countries. Studies in Peru with RRV-TV have shown a trend towards higher vaccine efficacy rates against “pure” (rotavirusonly) diarrheal episodes. Economic analyses made in the United States indicate that a vaccine that costs less than US$ 9 per dose would lead to a net savings in medical costs. To date, however, cost-benefit studies have not been done in developing countries. In the future, it is possible that some Latin American countries might adapt their polio production facilities to the preparation of rotavirus vaccines for human use. A year after RRV-TV was licensed for vaccination of infants in the United States, the occurrence of intussusception as an adverse event led to the vaccine’s withdrawal from the market. The implications of that action, particularly for Latin America, will be addressed in this article, including the need to explore alternative rotavirus candidate vaccines, particularly through the conduct of parallel clinical trials in both developed and developing countries. |
id |
IEC-2_3f6d470cbc62202cf7a09db1e2b2a325 |
---|---|
oai_identifier_str |
oai:patua.iec.gov.br:iec/3238 |
network_acronym_str |
IEC-2 |
network_name_str |
Repositório Digital do Instituto Evandro Chagas (Patuá) |
repository_id_str |
|
spelling |
Linhares, Alexandre da CostaBresee, Joseph S2018-07-16T17:01:09Z2018-07-16T17:01:09Z2000LINHARES, Alexandre da Costa; BRESEE, Joseph S. Rotavirus vaccines and vaccination in Latin America. Revista Panamericana de Salud Pública, v. 8, n. 5, p. 305-311, 2000.1020-4989https://patua.iec.gov.br/handle/iec/3238Worldwide, rotaviruses account for more than 125 million cases of infantile gastroenteritis and nearly 1 million deaths per year, mainly in developing countries. Rather than other control measures, vaccination is most likely to have a major impact on rotavirus disease incidence. The peak incidence of rotavirus diarrhea occurs between 6 and 24 months of age. In developing countries, however, cases are not uncommon among children younger than 6 months. G serotypes 1 to 4 are responsible for most disease, but there are indications that in Brazil that G type 5 is of emerging epidemiological importance. Both homotypic and heterotypic responses are elicited during natural rotavirus infection, and the immunological response at the intestinal mucosal surface is probably the more consistent predictor of clinical immunity. With the primary objective of protecting children against life-threatening dehydrating diarrhea, many approaches to rotavirus vaccine development have been attempted. One vaccine, the tetravalent rhesus-human reassortant rotavirus vaccine (RRV-TV), was given licensing approval in the United States of America, introduced to the market, and later withdrawn. A number of studies have found better efficacy of RRV-TV in developed countries than in developing ones. Field trials with a 4 10 plaque-forming units (PFU) preparation of RRVTV have been carried out in two countries in Latin America, Brazil and Peru. Those trials yielded protective efficacy rates against all rotavirus diarrhea ranging from 18% to 35%. Data from a large catchment trial in Venezuela with a higher RRV-TV dose, of 4 10 PFU/dose, indicated an efficacy rate of 48% against all rotavirus diarrhea and 88% against severe rotavirus diarrhea. It appears that breast-feeding does not compromise the efficacy of RRV-TV if three doses of the vaccine are administered. Similarly, possible interference of oral poliovirus vaccine with the “take” of the rotavirus vaccine can be overcome by giving three doses of the rotavirus vaccine or by using a higher-titer formulation of it. Wild enteroviruses, however, may cause primary rotavirus vaccine failure in developing countries. Studies in Peru with RRV-TV have shown a trend towards higher vaccine efficacy rates against “pure” (rotavirusonly) diarrheal episodes. Economic analyses made in the United States indicate that a vaccine that costs less than US$ 9 per dose would lead to a net savings in medical costs. To date, however, cost-benefit studies have not been done in developing countries. In the future, it is possible that some Latin American countries might adapt their polio production facilities to the preparation of rotavirus vaccines for human use. A year after RRV-TV was licensed for vaccination of infants in the United States, the occurrence of intussusception as an adverse event led to the vaccine’s withdrawal from the market. The implications of that action, particularly for Latin America, will be addressed in this article, including the need to explore alternative rotavirus candidate vaccines, particularly through the conduct of parallel clinical trials in both developed and developing countries.Ministério da Saúde. Fundação Nacional de Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.Centers for Disease Control and Prevention. Division of Viral and Rickettsial Diseases. Respiratory and Enteric Virus Branch. Atlanta, Georgia, United States of America.engWorld Health OrganizationRotavirus vaccines and vaccination in Latin Americainfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleVacinas contra Rotavirus / uso terapêuticoInfecções por Rotavirus / prevenção & controleinfo:eu-repo/semantics/openAccessreponame:Repositório Digital do Instituto Evandro Chagas (Patuá)instname:Instituto Evandro Chagas (IEC)instacron:IECORIGINALRotavirus vaccines and vaccination in Latin America.pdfRotavirus vaccines and vaccination in Latin America.pdfapplication/pdf275587https://patua.iec.gov.br/bitstreams/45145d73-b13f-4849-9948-9398477fa027/downloadf815b9c370cdb7e2d4215b1da2e5dfa8MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-871https://patua.iec.gov.br/bitstreams/87ef680f-3925-4860-84f4-e301f65227d9/download52f1732ea66fbd1123abe39f5373b797MD52TEXTRotavirus vaccines and vaccination in Latin America.pdf.txtRotavirus vaccines and vaccination in Latin America.pdf.txtExtracted texttext/plain100273https://patua.iec.gov.br/bitstreams/f96461f8-75e1-43a9-8d00-2bbff119158e/download5f7d79fe19fe626cf0256118cd8e37f8MD55THUMBNAILRotavirus vaccines and vaccination in Latin America.pdf.jpgRotavirus vaccines and vaccination in Latin America.pdf.jpgGenerated Thumbnailimage/jpeg4561https://patua.iec.gov.br/bitstreams/fd0cd1f4-a635-42c7-b0cc-df6078cf0f0e/downloadbd38868478d9375fe61e8a532b0f1592MD56iec/32382022-10-20 23:43:36.461oai:patua.iec.gov.br:iec/3238https://patua.iec.gov.brRepositório InstitucionalPUBhttps://patua.iec.gov.br/oai/requestclariceneta@iec.gov.br || Biblioteca@iec.gov.bropendoar:2022-10-20T23:43:36Repositório Digital do Instituto Evandro Chagas (Patuá) - Instituto Evandro Chagas (IEC)falseVG9kb3Mgb3MgZG9jdW1lbnRvcyBkZXNzYSBjb2xlw6fDo28gc2VndWVtIGEgTGljZW7Dp2EgQ3JlYXRpdmUgY29tbW9ucy4= |
dc.title.pt_BR.fl_str_mv |
Rotavirus vaccines and vaccination in Latin America |
title |
Rotavirus vaccines and vaccination in Latin America |
spellingShingle |
Rotavirus vaccines and vaccination in Latin America Linhares, Alexandre da Costa Vacinas contra Rotavirus / uso terapêutico Infecções por Rotavirus / prevenção & controle |
title_short |
Rotavirus vaccines and vaccination in Latin America |
title_full |
Rotavirus vaccines and vaccination in Latin America |
title_fullStr |
Rotavirus vaccines and vaccination in Latin America |
title_full_unstemmed |
Rotavirus vaccines and vaccination in Latin America |
title_sort |
Rotavirus vaccines and vaccination in Latin America |
author |
Linhares, Alexandre da Costa |
author_facet |
Linhares, Alexandre da Costa Bresee, Joseph S |
author_role |
author |
author2 |
Bresee, Joseph S |
author2_role |
author |
dc.contributor.author.fl_str_mv |
Linhares, Alexandre da Costa Bresee, Joseph S |
dc.subject.decsPrimary.pt_BR.fl_str_mv |
Vacinas contra Rotavirus / uso terapêutico Infecções por Rotavirus / prevenção & controle |
topic |
Vacinas contra Rotavirus / uso terapêutico Infecções por Rotavirus / prevenção & controle |
description |
Worldwide, rotaviruses account for more than 125 million cases of infantile gastroenteritis and nearly 1 million deaths per year, mainly in developing countries. Rather than other control measures, vaccination is most likely to have a major impact on rotavirus disease incidence. The peak incidence of rotavirus diarrhea occurs between 6 and 24 months of age. In developing countries, however, cases are not uncommon among children younger than 6 months. G serotypes 1 to 4 are responsible for most disease, but there are indications that in Brazil that G type 5 is of emerging epidemiological importance. Both homotypic and heterotypic responses are elicited during natural rotavirus infection, and the immunological response at the intestinal mucosal surface is probably the more consistent predictor of clinical immunity. With the primary objective of protecting children against life-threatening dehydrating diarrhea, many approaches to rotavirus vaccine development have been attempted. One vaccine, the tetravalent rhesus-human reassortant rotavirus vaccine (RRV-TV), was given licensing approval in the United States of America, introduced to the market, and later withdrawn. A number of studies have found better efficacy of RRV-TV in developed countries than in developing ones. Field trials with a 4 10 plaque-forming units (PFU) preparation of RRVTV have been carried out in two countries in Latin America, Brazil and Peru. Those trials yielded protective efficacy rates against all rotavirus diarrhea ranging from 18% to 35%. Data from a large catchment trial in Venezuela with a higher RRV-TV dose, of 4 10 PFU/dose, indicated an efficacy rate of 48% against all rotavirus diarrhea and 88% against severe rotavirus diarrhea. It appears that breast-feeding does not compromise the efficacy of RRV-TV if three doses of the vaccine are administered. Similarly, possible interference of oral poliovirus vaccine with the “take” of the rotavirus vaccine can be overcome by giving three doses of the rotavirus vaccine or by using a higher-titer formulation of it. Wild enteroviruses, however, may cause primary rotavirus vaccine failure in developing countries. Studies in Peru with RRV-TV have shown a trend towards higher vaccine efficacy rates against “pure” (rotavirusonly) diarrheal episodes. Economic analyses made in the United States indicate that a vaccine that costs less than US$ 9 per dose would lead to a net savings in medical costs. To date, however, cost-benefit studies have not been done in developing countries. In the future, it is possible that some Latin American countries might adapt their polio production facilities to the preparation of rotavirus vaccines for human use. A year after RRV-TV was licensed for vaccination of infants in the United States, the occurrence of intussusception as an adverse event led to the vaccine’s withdrawal from the market. The implications of that action, particularly for Latin America, will be addressed in this article, including the need to explore alternative rotavirus candidate vaccines, particularly through the conduct of parallel clinical trials in both developed and developing countries. |
publishDate |
2000 |
dc.date.issued.fl_str_mv |
2000 |
dc.date.accessioned.fl_str_mv |
2018-07-16T17:01:09Z |
dc.date.available.fl_str_mv |
2018-07-16T17:01:09Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
LINHARES, Alexandre da Costa; BRESEE, Joseph S. Rotavirus vaccines and vaccination in Latin America. Revista Panamericana de Salud Pública, v. 8, n. 5, p. 305-311, 2000. |
dc.identifier.uri.fl_str_mv |
https://patua.iec.gov.br/handle/iec/3238 |
dc.identifier.issn.-.fl_str_mv |
1020-4989 |
identifier_str_mv |
LINHARES, Alexandre da Costa; BRESEE, Joseph S. Rotavirus vaccines and vaccination in Latin America. Revista Panamericana de Salud Pública, v. 8, n. 5, p. 305-311, 2000. 1020-4989 |
url |
https://patua.iec.gov.br/handle/iec/3238 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
World Health Organization |
publisher.none.fl_str_mv |
World Health Organization |
dc.source.none.fl_str_mv |
reponame:Repositório Digital do Instituto Evandro Chagas (Patuá) instname:Instituto Evandro Chagas (IEC) instacron:IEC |
instname_str |
Instituto Evandro Chagas (IEC) |
instacron_str |
IEC |
institution |
IEC |
reponame_str |
Repositório Digital do Instituto Evandro Chagas (Patuá) |
collection |
Repositório Digital do Instituto Evandro Chagas (Patuá) |
bitstream.url.fl_str_mv |
https://patua.iec.gov.br/bitstreams/45145d73-b13f-4849-9948-9398477fa027/download https://patua.iec.gov.br/bitstreams/87ef680f-3925-4860-84f4-e301f65227d9/download https://patua.iec.gov.br/bitstreams/f96461f8-75e1-43a9-8d00-2bbff119158e/download https://patua.iec.gov.br/bitstreams/fd0cd1f4-a635-42c7-b0cc-df6078cf0f0e/download |
bitstream.checksum.fl_str_mv |
f815b9c370cdb7e2d4215b1da2e5dfa8 52f1732ea66fbd1123abe39f5373b797 5f7d79fe19fe626cf0256118cd8e37f8 bd38868478d9375fe61e8a532b0f1592 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Digital do Instituto Evandro Chagas (Patuá) - Instituto Evandro Chagas (IEC) |
repository.mail.fl_str_mv |
clariceneta@iec.gov.br || Biblioteca@iec.gov.br |
_version_ |
1787533075558694912 |